Elsevier

Pharmacological Research

Volume 120, June 2017, Pages 88-96
Pharmacological Research

Review
The interplay between Angiotensin II, TLR4 and hypertension

https://doi.org/10.1016/j.phrs.2017.03.017Get rights and content

Abstract

Hypertension is a multifactorial disease. Although a number of different underlying mechanisms have been learned from the various experimental models of the disease, hypertension still poses challenges for treatment. Angiotensin II plays an unquestionable role in blood pressure regulation acting through central and peripheral mechanisms. During hypertension, dysregulation of the Renin-Angiotensin System is associated with increased expression of pro-inflammatory cytokines and reactive oxygen species causing kidney damage, endothelial dysfunction, and increase in sympathetic activity, among other damages, eventually leading to decline in organ function. Recent studies have shown that these effects involve both the innate and the adaptive immune response. The contribution of adaptive immune responses involving different lymphocyte populations in various models of hypertension has been extensively studied. However, the involvement of the innate immunity mediating inflammation in hypertension is still not well understood. The innate and adaptive immune systems intimately interact with one another and are essential to an effectively functioning of the immune response; hence, the importance of a better understanding of the underlying mechanisms mediating innate immune system during hypertension. In this review, we aim to discuss mechanisms linking Angiotensin II and the innate immune system, in the pathogenesis of hypertension. The newest research investigating Angiotensin II triggering toll like receptor 4 activation in the kidney, vasculature and central nervous system contributing to hypertension will be discussed. Understanding the role of the innate immune system in the development of hypertension may bring to light new insights necessary to improve hypertension management.

Introduction

Despite considerable advances in therapeutic management, the prevalence of hypertension and its contribution to death and disability continue to be a major public health challenge [1]. The etiology of hypertension is multifactorial, highly complex, and involves interplay between peripheral cardiovascular organs and the central nervous system (CNS). Among the various mechanisms contributing to the development of hypertension, it is well established that the dysregulation of Renin-Angiotensin System (RAS) plays a critical role in the generation and maintenance of the disease. Classically, RAS produces the active metabolite Angiotensin II (AngII) from angiotensinogen substrate primarily of hepatic origin [2]. Circulating AngII causes hypertension through direct actions in the kidney and blood vessels, and also by accessing the CNS. In addition to circulating AngII, tissue RAS, being able to produce AngII locally, has also been found in organs systems/organs such as the cardiovascular system, kidneys, and CNS, among others [3]. In the last few years, a large number of experimental studies have further demonstrated that local/tissue AngII is involved in key events of the inflammatory process, especially during hypertension. Indeed, the presence of immune components displaying a low-grade inflammation has been associated with hypertension. Several studies have discussed the contribution of adaptive immune responses involving different lymphocyte populations in various models of hypertension. However, the involvement of innate immunity, which is responsible for activation of adaptive response, mediating inflammation in hypertension, is still not well understood [4], [5], [6].

The innate immune system relies on pattern recognition receptors, of which, the family of Toll-like receptors (TLRs) has been most extensively studied. TLRs recognize a variety of pathogen-associated molecular patterns (PAMPs) and endogenous stress signals termed damage-associated molecular patterns (DAMPs) [7]. Activated intracellular domains of TLRs initiate a series of downstream signaling cascades through adaptor proteins, triggering an inflammatory response and subsequently interacting with the adaptive immune system for a more robust and specific response [8].

From the group of thirteen characterized TLRs, the most well-defined TLR involved in the etiology of hypertension is TLR4 [7], which will be the focus of this review. TLR4 induces inflammatory response by activation of two main pathways: 1) the myeloid differentiation primary-response protein 88 (MyD88)-dependent pathway, which involves the early phase of nuclear factor-κB (NF-κB) activation with consequent production of inflammatory cytokines; and 2) MyD88-independent pathways, which involves the late phase of NF-κB activation by activating interferon (IFN)-regulatory factor 3, leading to the production of IFN-β and the expression of IFN-inducible genes [8]. Early phase activation of NF-κB via MyD88-dependent pathway subsequently mediates the transcription of cyclooxygenase 2 (COX2) and pro-inflammatory cytokine genes [9]. COX2 is particularly important in the hypertension context because of its production of prostaglandins and subsequently thromboxane A2, a vasoconstrictor able to increase blood pressure [9].

Besides its classic role in the regulation of circulatory homeostasis, AngII acting mainly through Angiotensin type 1 receptor (AT1r) is acknowledged to act as a powerful pro-inflammatory mediator [10].

An association between AngII, inflammation, and increase in blood pressure, appears to play an important role in the kidney, vascular, and CNS alterations linked to hypertension. AngII inflammatory effects are mediated, in part, by activation of nuclear factor kappa-B (NF-κB), and the production of inflammatory mediators, including interleukin (IL)-1β, IL-6, and tumor necrosis factor (TNF). In that context, it has been shown that AT1r antagonist treatment reduced vascular expression of NF-κB in Spontaneously Hypertensive Rats (SHR), associated with reduction of IL-1β, and IL-6 [11]. An association between AngII and IL-6 mediating renal vasoconstriction [12] and chronic kidney disease [13] in experimental AngII-induced hypertension; as well as a role for IL-6 in AngII-mediated hypertension in human subjects has also been supported [14]. Within the CNS, central blockade of NF-κB decreases pro-inflammatory cytokines attenuating hypothalamic sympathoexcitation of AngII-induced hypertension [15]. Likewise, AngII-dependent hypertension is prevented by chronic blockade of TNF within the brain [16].

AngII, via AT1r, also stimulates nicotinamide adenine dinucleotide phosphate (NADPH) oxidase (Nox enzymes) and generates reactive oxygen species (ROS) [17]. Redox signaling within the vascular, kidney, and neuronal systems are implicated with hypertension. ROS contributes to endothelial dysfunction by inactivating nitric oxide [18], and to vascular inflammation by stimulating NF-κB, and upregulation of cytokines [19]. In AngII-dependent chronic hypertension, ROS, via Nox1, is associated with renal damage [20]. Within the CNS, ROS is associated with increases in neuronal activity and sympathetic outflow [21], [22], alongside with its influence in peripheral organs during hypertension [23].

As briefly discussed above, there is a consensus that inflammatory processes induced by AngII dysregulation, accompanied by the release of pro-inflammatory cytokines, and ROS, contributes to altered mean arterial blood pressure. Thus, suggesting that hypertension induced by AngII inflammatory signaling is associated with the activation of the immune system. There are excellent recent reviews in the literature covering the role of both adaptive and innate immune responses in hypertension [4], [6], [24], [25]. Our intent is concentrate our focus on AngII inflammatory actions involving the innate immune system via TLRs.

Recent studies have shown upregulation of TLR4 in the generation and maintenance of hypertension dependent on AngII. In this review, we aim to discuss the contribution of the innate immune system through the interactions of TLR4 and AngII within the kidney, vasculature, and CNS during hypertension.

Section snippets

AngII and TLR4 in hypertension: the kidneys

As the major biologically active hormone generated by the RAS system, AngII has powerful effects in controlling blood pressure and sodium homeostasis via the kidneys. In the renal system, AngII has a direct effect on the proximal tubules to increase sodium reabsorption and it has a complex and variable effect on glomerular filtration and renal blood flow depending on the setting [26]. Additionally, AngII acts on the adrenal cortex to stimulate the synthesis and secretion of aldosterone, a

Vascular inflammation, AngII, and TLR4 in hypertension

The RAS system plays a crucial role in the initiation and maintenance of vascular inflammation and the vascular remodeling characteristic of hypertension [48]. AngII mediates vasoconstriction, endothelial dysfunction, vascular remodeling, inflammation, and fibrosis, via multiple pathogenic mechanisms [49]. For example, it influences vascular permeability by increasing production of vascular endothelial growth factor. AngII also increases the expression of chemokines and cytokines, resulting in

Ang II, TLR4 and brain inflammation during hypertension

AngII plays a critical role in the regulation of cardiovascular function within the CNS. During normal conditions, AngII is a large hydrophilic peptide that normally does not cross the blood brain barrier (BBB). Circulating AngII is thought to gain access to the brain through neural areas devoid of BBB, namely the sensory circumventricular organs (CVOs) [59]. In the CVOs, AngII signaling influences cardiovascular control by activating key central pathways involved in blood pressure regulation

AngII-TLR4 crosstalk: signaling pathways

AngII has been found to increase oxidative stress and aggravate ROS production during hypertension by activating NADPH oxidases, subsequently stimulating multiple ROS-sensitive signaling cascades, and promoting release of inflammatory response factors, such as TNF-α, interleukins (IL)-1β, IL-6, and IL-12 [16], [103], [104]. In addition to this direct pro-inflammatory effect of RAS on its own, a putative indirect and/or modulatory role of AngII through crosstalk with TLR4 has been proposed

Final remarks

An association between the immune system and hypertension has long been recognized. The role of the adaptive immune system and lymphocytes has been well characterized. However, the contribution of the innate immune system in the etiology of hypertension, particularly via toll like receptors, is less understood. The activation or prime of the innate immune system ultimately leads the adaptive immune system to a more robust response; hence, it constitutes an important area of investigation.

A

Author Agreement/Declaration

All authors have seen and approved the final version of the manuscript being submitted.

Conflict of Interest

No conflicts exist.

Funding

This work was supported by the American Heart Association (grant number 14SDG20400015 to VCB and 12SDG12080023 to KPN).

References (116)

  • S.H. Appel et al.

    T cell-microglial dialogue in Parkinson's disease and amyotrophic lateral sclerosis: are we listening?

    Trends Immunol.

    (2010)
  • M.A. Lopes Pinheiro et al.

    Immune cell trafficking across the barriers of the central nervous system in multiple sclerosis and stroke

    Biochim. Biophys. Acta

    (2016)
  • H.B. Li et al.

    TLR4/MyD88/NF-kappaB signaling and PPAR-gamma within the paraventricular nucleus are involved in the effects of telmisartan in hypertension

    Toxicol. Appl. Pharmacol.

    (2016)
  • J. Rodriguez-Pallares et al.

    Brain angiotensin enhances dopaminergic cell death via microglial activation and NADPH-derived ROS

    Neurobiol. Dis.

    (2008)
  • Q. Su et al.

    Inhibition of reactive oxygen species in hypothalamic paraventricular nucleus attenuates the renin-angiotensin system and proinflammatory cytokines in hypertension

    Toxicol. Appl. Pharmacol.

    (2014)
  • M. Zhang et al.

    Angiotensin II induced cerebral microvascular inflammation and increased blood-brain barrier permeability via oxidative stress

    Neuroscience

    (2010)
  • S.S. Yoon et al.

    Trends in blood pressure among adults with hypertension: United States, 2003 to 2012

    Hypertension

    (2015)
  • A.R. Brasier et al.

    Mechanisms for inducible control of angiotensinogen gene transcription

    Hypertension

    (1996)
  • M. Paul et al.

    Physiology of local renin-angiotensin systems

    Physiol. Rev.

    (2006)
  • M.O. Mian et al.

    Innate immunity in hypertension

    Curr. Hypertens. Rep.

    (2014)
  • M.V. Singh et al.

    Toll-like receptors and hypertension

    Am. J. Physiol. Regul. Integr. Comp. Physiol.

    (2014)
  • W.G. McMaster et al.

    Inflammation, immunity, and hypertensive end-organ damage

    Circ. Res.

    (2015)
  • C.G. McCarthy et al.

    Toll-like receptors and damage-associated molecular patterns: novel links between inflammation and hypertension

    Am. J. Physiol. Heart Circ. Physiol.

    (2014)
  • S. Akira et al.

    Toll-like receptor signalling

    Nat. Rev. Immunol.

    (2004)
  • G.F. Bomfim et al.

    Toll-like receptor 4 contributes to blood pressure regulation and vascular contraction in spontaneously hypertensive rats

    Clin. Sci. (Lond)

    (2012)
  • D. Sanz-Rosa et al.

    Effect of AT1 receptor antagonism on vascular and circulating inflammatory mediators in SHR: role of NF-kappaB/IkappaB system

    Am. J. Physiol. Heart Circ. Physiol.

    (2005)
  • M.W. Brands et al.

    Interleukin 6 knockout prevents angiotensin II hypertension: role of renal vasoconstriction and janus kinase 2/signal transducer and activator of transcription 3 activation

    Hypertension

    (2010)
  • W. Zhang et al.

    Interleukin 6 underlies angiotensin II-induced hypertension and chronic renal damage

    Hypertension

    (2012)
  • B. Chamarthi et al.

    Inflammation and hypertension: the interplay of interleukin-6, dietary sodium, and the renin-angiotensin system in humans

    Am. J. Hypertens.

    (2011)
  • Y.M. Kang et al.

    Brain nuclear factor-kappa B activation contributes to neurohumoral excitation in angiotensin II-induced hypertension

    Cardiovasc. Res.

    (2009)
  • S. Sriramula et al.

    Inhibition of TNF in the brain reverses alterations in RAS components and attenuates angiotensin II-induced hypertension

    PLoS One

    (2013)
  • M.R. Tschudi et al.

    Direct in situ measurement of nitric oxide in mesenteric resistance arteries. Increased decomposition by superoxide in hypertension

    Hypertension

    (1996)
  • M. Ruiz-Ortega et al.

    Angiotensin II activates nuclear transcription factor kappaB through AT(1) and AT(2) in vascular smooth muscle cells: molecular mechanisms

    Circ. Res.

    (2000)
  • A. Yogi et al.

    Renal redox-sensitive signaling, but not blood pressure, is attenuated by Nox1 knockout in angiotensin II-dependent chronic hypertension

    Hypertension

    (2008)
  • C. Sun et al.

    NAD(P)H oxidase inhibition attenuates neuronal chronotropic actions of angiotensin II

    Circ. Res.

    (2005)
  • L. Gao et al.

    Sympathoexcitation by central ANG II: roles for AT1 receptor upregulation and NAD(P)H oxidase in RVLM

    Am. J. Physiol. Heart Circ. Physiol.

    (2005)
  • H.E. Lob et al.

    Induction of hypertension and peripheral inflammation by reduction of extracellular superoxide dismutase in the central nervous system

    Hypertension

    (2010)
  • J.M. Abais-Battad et al.

    Hypertension and immunity: mechanisms of T cell activation and pathways of hypertension

    Curr. Opin. Nephrol. Hypertens.

    (2015)
  • M.V. Singh et al.

    The immune system and hypertension

    Immunol. Res.

    (2014)
  • M.A. Sparks et al.

    Classical Renin-Angiotensin system in kidney physiology

    Compr. Physiol.

    (2014)
  • N. Munoz-Durango et al.

    Role of the renin-angiotensin-aldosterone system beyond blood pressure regulation: molecular and cellular mechanisms involved in end-organ damage during arterial hypertension

    Int. J. Mol. Sci.

    (2016)
  • H. Kobori et al.

    The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease

    Pharmacol. Rev.

    (2007)
  • A.K. Bidani et al.

    Pathophysiology of hypertensive renal damage: implications for therapy

    Hypertension

    (2004)
  • S. Lodha et al.

    Angiotensin II-induced mesangial cell apoptosis: role of oxidative stress

    Mol. Med.

    (2002)
  • G. Wolf et al.

    Angiotensin II upregulates toll-like receptor 4 on mesangial cells

    J. Am. Soc. Nephrol.

    (2006)
  • G. Wolf

    Role of reactive oxygen species in angiotensin II-mediated renal growth, differentiation, and apoptosis

    Antioxid. Redox. Signal

    (2005)
  • H. Sugiyama et al.

    Role of apoptosis in renal injury

    Nihon Rinsho

    (1996)
  • S.I. Dikalov et al.

    Angiotensin II-induced production of mitochondrial reactive oxygen species: potential mechanisms and relevance for cardiovascular disease

    Antioxid. Redox. Signal

    (2013)
  • S. Frantz et al.

    Mechanisms of disease: Toll-like receptors in cardiovascular disease

    Nat. Clin. Pract. Cardiovasc. Med.

    (2007)
  • R. Spirig et al.

    The emerging role of TLR and innate immunity in cardiovascular disease

    Cardiol. Res. Pract.

    (2012)
  • Cited by (105)

    • Angiotensin II and its action within the brain during hypertension

      2023, Angiotensin: From the Kidney to Coronavirus
    • Hypotension as a marker or mediator of perioperative organ injury: a narrative review

      2022, British Journal of Anaesthesia
      Citation Excerpt :

      Thus, both sterile and infectious inflammation share this ancient, conserved receptor. Unfortunately, TLR4 is upregulated by both hypoxia55 and angiotensin II,56,57 a pivotal player in the development of high blood pressure, in multiple cell types, including renal mesangial,58 cardiac,59 microglial,60 smooth muscle,61 and peripheral immune cells.62 Systemic TLR4 blockade and inherited functional mutations in the TLR4 gene reduce blood pressure and limit end-organ damage in a variety of experimental models of hypertension.63

    View all citing articles on Scopus
    View full text